Read More

Nkarta Announces Updated Clinical Data From Phase 1 Dose Escalation Study Of NKX019; Says ‘7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response’

7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)   5 CRs achieved across all dose levels after a single cycle (3

NKTX